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Abstract
Drug resistance of Streptococcus suis strains is a worldwide problem for both humans and pigs. Previous studies have noted
that penicillin-binding protein (PBPs) mutation is one important cause of b-lactam antibiotic resistance. In this study, we
used the molecular dynamics (MD) method to study the interaction differences between cefuroxime (CES) and PBP2x within
two newly sequenced Streptococcus suis: drug-sensitive strain A7, and drug-resistant strain R61. The MM-PBSA results
proved that the drug bound much more tightly to PBP2x in A7 (PBP2x-A7) than to PBP2x in R61 (PBP2x-R61). This is
consistent with the evidently different resistances of the two strains to cefuroxime. Hydrogen bond analysis indicated that
PBP2x-A7 preferred to bind to cefuroxime rather than to PBP2x-R61. Three stable hydrogen bonds were formed by the drug
and PBP2x-A7, while only one unstable bond existed between the drug and PBP2x-R61. Further, we found that the Gln569,
Tyr594, and Gly596 residues were the key mutant residues contributing directly to the different binding by pair wise energy
decomposition comparison. By investigating the binding mode of the drug, we found that mutant residues Ala320, Gln553,
and Thr595 indirectly affected the final phenomenon by topological conformation alteration. Above all, our results revealed
some details about the specific interaction between the two PBP2x proteins and the drug cefuroxime. To some degree, this
explained the drug resistance mechanism of Streptococcus suis and as a result could be helpful for further drug design or
improvement.
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Introduction
The worldwide Streptococcus suis pathogen is a serious problem
for both humans and pigs. This pathogen can lead to meningitis,
endocarditis, septicemia, septic arthritis, pneumonia, and abortion
in pig, and it can subsequently infect humans via direct contact [1–
3]. To treat or resist this pathogen, multi-antimicrobials have been
used extensively in recent years. Multi-antimicrobials, particularly
b-lactam antibiotics, are the most popular antibiotics owing to
their comparatively high efficiency, low cost, delivery convenience,
and minimal side effects [4]. However, drug resistance often arises
to these antimicrobials [5–11]. Further complicating the problem,
the number of newly designed drugs to treat or resist this pathogen
continually decreases [12]. Therefore, intensive study of the
specific drug resistance mechanism of Streptococcus suis is of utmost
importance for further research and treatment of the pathogen.
Previous studies have noted that target protein mutation is a
decisive reason for drug resistance. Within the protein category,
PBPs proteins, which play essential roles in constructing bacteria’s
cell walls, are particularly important [13–18]. In the b-lactam-
resistant S. pneumonia, the coding genes of PBPs introduce many
substitutions throughout the entire protein. This subsequently
causes these genes to lose their affinity with the antibiotics [19–22].
Based on an MIC test, Hu et al.’s research data indicated that
Streptococcus suis R61 was resistant to b-lactam. The reason for this
resistance may be attributed to the mutation of the drug’s target
protein: PBP2x [23]. Here, we investigated the specific interaction
between PBP2x and cefuroxime (CES) in two Streptococcus suis: the
drug-sensitive strain A7 (S. suis A7), and the drug-resistant strain
R61 (S. suis R61). We did so using the molecular dynamic method
(MD).
MD simulation is a powerful tool for studying the binding
mechanism at the atomic level [24–28]. In this study, we used MD
simulation to investigate the detailed interactions between PBPs
and CES in order to explore the drug resistance mechanism. First,
we constructed the complex structure of PBP-2x proteins and
cefuroxime by Modeller [29]. With the help of the Amber software
package [30], we carried out a comparative dynamics study of the
binding mode between two different proteins and their interaction
with the drug. Our research returned several useful conclusions
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35941that could be conducive to understanding the drug resistance
mechanism of Streptococcus suis. Further, these conclusions may be
beneficial to further drug design for protection of infected animals
and humans.
Methods
Model Construction
Four PBPs were identified by sequence similarities searching in
S. suis R61 and S. suis A7: pbp2x, pbp2b, pbp1a, and pbp2a. A
previous report demonstrated that PBP2x is the primary PBP
target in b-lactam-resistant S. pneumoniae strains [13]. Further,
PBP2x in the drug resistant R61 strain here showed more
mutations than that in the S.suis A7 and that in the other S. suis
[23]. In this study, we adapted the homology modeling method to
construct the three-dimensional structures of the target proteins. A
crystallized complex consisting of the PBP2x protein and the
cefuroxime in Streptococcus pneumoniae (PDB code 1QMF) has been
reported in a previous study [13]. Recently, this complex structure
has allowed research involving resistance pattern analysis of S.suis
R61 to b-lactam antibiotics to take place [23]. Accordingly, we
made use of this complex structure (PDB code 1QMF) to produce
our target protein. Unfortunately, the N terminal region from 1 to
200 has not been clearly and continuously resolved. As a
consequence, the N terminal region was not completely included
in our modeled structures. This is an unavoidable shortcoming
within our research structure due to an external constraint.
However, the two proteins did have complete transpeptidase and
C terminal regions, in which the mutant sites of the drug-sensitive
strain R61 compared to the drug-resistant strain A7 mostly
located. The former region was proven to be the functional area
for drug interaction. Further, the MD study indicated that the
whole system reached equilibrium after about 8 ns. This could be
verified by the RMSD plot of both the complex and the drug
molecule. It could also be verified by other indices like
Temperature, Density, and Total Energy (Data not shown). This
meant that our further analysis was reasonable. This further
indicated that the whole study would be helpful for exploring the
binding characters between the PBP2x proteins and the
cefuroxime (CES) in the drug-resistant and drug-sensitive strains.
The sequence alignment of the target protein and the template
protein was performed using Modeller V8.1 and the Blosum 62
Matrix. We adopted the basic modeling method to produce the
structures, leaving the loop regions optimized in the further
minimization and MD stage. The pdb files of model proteins were
generated for each target protein using spatial structure restraints
based on the sequence alignment data. Then the Procheck [31],
Dope [32], and Ga341 [33] methods were applied to evaluate the
quality of these candidate models. For each modeled structure
produced, the Procheck, Dope, and Ga341 methods gave an
evaluation score. Procheck identified the exact percentage of
amino acids located in the allowed regions. Dope and Ga341
scores provided an evaluation index integrated in the evaluation
modules of Modeller to assess the produced model’s quality. This
could be achieved by the log file in running Modeller. The higher
these scores were, the better the quality of the structure was
assessed to be. We chose the model that had the highest score
under these evaluation criteria, and then we performed the
refinement step. First, 5000 iterations of the steepest descent (SD)
calculation were carried out. Then, the conjugated gradient (CG)
calculation was implemented until the convergence on the
gradient reached 0.05 kcal/(A ˚ mol). After simulations were
performed, the homology models were obtained via the molecular
dynamics (MD) calculation. This was done in the Amber software
package under the AMBERff99SB force field to proceed with the
optimization. The rectangular box used in Amber by Xleap to add
water molecules to solve the simulated complex is not cubic and it
is infinitely repeated in space by the periodic boundary method,
leading the ends of the complex close to their periodic images. If a
list of numbers are specified to the solvateBox command in Xleap
to make the box cubic, the simulated complex will be significantly
added more water; consequently, the calculation will slow down
enormously. In terms of reducing the problem of solute rotation, a
more efficient shaped box of water to use would be a truncated
octahedron [34]. Hence, we add a truncated octahedral box of
water to solve the protein and keep the simulation temperature at
300 K. Finally, a conjugate gradient energy minimization of the
full protein was performed until the root mean-square (rms)
gradient energy was lower than 0.001 kcal/(A ˚ mol). The quality of
the initial protein model was improved after completion of all the
above steps.
The complex structure involving PBP2x and cefuroxime was
produced by sequence alignment data on the basis of the template
protein (PDB code 1QMF). The geometry of the drug was
optimized at the HF/6-31G level. Partial atomic charges of the
cefuroxime molecule were assigned by DFT calculations at the
B3LYP/cc-pVTZ level and fitted with the RESP procedure [35].
The atom types were assigned using the Antechamber module
[36] in Amber 9. We chose the Antechamber module to obtain the
topology file of the drug for the subsequent Amber simulation. At
this point the entire structure of this complex was ready for MD
simulation.
Molecular Dynamic (MD) Simulation
MD simulations were performed at the molecular mechanics
level using the Amber 9 program package with the AMBERff99SB
force field [30]. Structures of the complex models were solvated in
a truncated octahedral box of TIP3P water that extended at least
12 A ˚ in each direction in the solute. To calculate the nonbonded
interactions, the cut-off distance was kept at 12 A ˚. Before MD
simulations took place, the systems were relaxed by a series of
steepest descent (SD) and conjugated gradient (CG) minimizations.
MD simulations were applied to these minimized systems by
gradually heating over 50 ps from 0 to 300 K with the protein
backbone atoms fixed using a force constant of 2 kcal/(mol A ˚ 2).
Then, we carried out 50 ps density equilibration with the same
restraints on the protein backbone. The following step was
constant pressure equilibration at 300 K. The periodic boundary
was used to keep the pressure constant by setting the correspond-
ing parameters: PRES0=1.0, NTP=1, and TAUP=2.0. Isotro-
pic position scaling was used to maintain the pressure (NTP=1); a
constant pressure periodic boundary with an average pressure of 1
atm (PRES0) and a relaxation time of 2 ps were used
(TAUP=2.0).
The two complexes in the study were very large, especially when
the water molecules were added to solvate the complex. For
reasons of computational time and resource use, we simulated
each of the two complexes for 16 ns to explore the binding
difference. Also, after simulation for 16 ns, the trend became clear
for both complexes. That is, the RMSD value indicated that the
complexes began to converge from approximately 8 ns. Other
indices such as Temperature, Density, and Total Energy all
proved that the system converged in the whole equilibrium period
(Data not shown). All simulations were performed under periodic
boundary conditions, and long-range electrostatics were treated
using the Particle-Mesh-Ewald method. The time step was set to 2
fs and the trajectory was recorded every 2 ps with shake on
hydrogen atoms. For temperature control we used the Langevin
MD Simulation of the Complex PBP2x with Cefuroxime
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at 300 K. This temperature control method used Langevin
dynamics with a collision frequency given by GAMMA_LN=1.0.
MD Analysis
To assess the stability of MD trajectories, the root-mean-square
deviation (RMSD) of the complex backbone atoms relative to the
starting structure during the MD production phase was calculated.
The calculation was performed under the PTRAJ module in the
Amber program suite. MD simulations can explicitly analyze
hydrogen bond properties, such as donor-acceptor assignments
and hydrogen bond occupancies. The criteria to identify hydrogen
bonds include: (1) the distance between proton donor (X) and
acceptor (Y) atoms is less than or equal to 3.5 A ˚; and (2) the angle
X-H…Y is greater than or equal to 120u. Here, special attention
was given to stable hydrogen bonds, which hold this mode for at
least 40% of the simulation period [37].
The binding free energy between the protein and the drug was
computed using the MM-GBSA (Molecular Mechanics General-
ized Born Surface Area) and MM-PBSA (Molecular Mechanics
Poisson–Boltzmann Surface Area) methods in Amber SANDER
modules [38]. Early versions of Amber require an external poisson
Boltzmann solver such as Delphi, but it was possible to use the
internal PBSA program in the software used in this study. The GB
method was determined by the IGB parameter. Here we set gb=2
by turning on the Onufriev, Bashford, Case (OBC) variant of GB
with a=0.8, b=0.0, and g=2.909 [39]. Nonpolar contribution to
the solvation free energy, represented by PBSUR/GBSUR in
Table 1, was calculated using solvent-accessible-surface-area-
dependent terms [40–41]. The surface area is computed with
Paul Beroza’s molsurf program, which is based on analytical ideas
primarily developed by Mike Connolly [42].
In this approach, the trajectory frames were stripped off of
counter-ions and water molecules. Further, the decomposed
interaction energy of each residue was calculated to obtain a
detailed view of the specific binding. These decompositions are
possible for molecular mechanics and free energy of solvation, but
not for entropies. The details of the underlying theory are
described elsewhere [43].
Results and Discussion
Sequence Alignments and Model Construction of the
Complex
The sequence alignment of PBP2x-R61, PBP2x-A7, and the
template protein (PDB code 1QMF) were obtained by ClustalW
[44] and viewed using Genedoc [45–47] (Figure 1). It could be
seen that PBP2x-R61 and PBP2x-A7 were both very similar to the
template. The identities of PBP2x-R61 and PBP2x-A7 compared
to the template were 56.70% and 56.34%, respectively. Amongst
homologues, protein structures are more conserved than protein
sequences, but sequences falling below a 25% sequence identity
could have a very different structure [48]. Additionally, evolu-
tionarily-related proteins have similar sequences, and naturally
occurring homologous proteins have similar protein structures.
However, due to sequence conservation, the three-dimensional
protein structure tends to be evolutionarily more conserved than it
is expected to be [49]. Further, in Modeller, a sequence identity
value above approximately 25% generally indicates a potential
template. This means that it is capable of producing the target
structures with the homology modeling method. The qualities of
the model proteins here were evaluated by Procheck (Figure 2).
The Ramachandran plot showed that 84.5% PBP2x-R61 residues
and 85.0% PBP2x-A7 residues were located in the most favored
regions. 12.8% PBP2x-R61 and 11.0% PBP2x-R61 residues were
located in additionally allowed regions. This outcome was
comparable with the high-quality crystallographic structures
determined at a resolution of 2.8 A ˚. Considering further
optimization would be executed by Amber, this result suggested
that the backbone conformations of these two complexes were
acceptable.
The produced three-dimensional structures of the two proteins
had a central transpeptidase domain (residues 265–619), which is
the classical class A structure of the PBP protein [50]. It has been
reported that the central domain is the active site area and plays
an important role in drug interaction [13–14,51]. We could see
that this central domain region surrounded the drug molecule
(Figure 3A). Although the figure showed that the two-modeled
proteins were very similar to one another, the RMSD (root-mean-
squared-deviation) value was 5.57 A ˚. This indicated the original
influence of the mutated residues. In fact, there were 165 total
mutated sites of PBP2x-R61 compared to PBP2x-A7. Most of
them were located in the loop regions of the transpeptidase and C-
terminal domain.
Stability of the Complex’s MD Trajectories
In this study, we simulated more than 16 ns to ensure that the
equilibration phase lasted long enough for further binding energy
and hydrogen binding mode analysis. The stability was evaluated
by the RMSD values of the backbone atoms in the two complexes
(Figure 4A) and those of the drug molecule alone (Figure 4B)
relative to those in the starting structure of the heating phase. The
trajectories of the whole complex were stable after simulation for
about 8 ns (Figure 4A). Snapshots from this time through the end
Table 1. Binding free energies (kcal/mol) between PBP2x
protein and cefuroxime (CES) in the two complexes.
Method Contribution Complex
PBP2x-R61-CES PBP2x-A7-CES
MM ELE 212.763.9 224.064.9
VDW 241.663.3 258.162.9
INT 0.060.2 0.061.1
GAS 254.264.9 282.165.9
PBSA PBSUR 25.960.3 26.160.1
PBCAL 42.965.9 51.764.3
PBSOL 37.065.8 45.664.3
PBELE 30.264.1 27.762.9
PBTOT 217.264.2 236.464.9
GBSA GBSUR 25.960.3 26.160.1
GB 31.763.5 39.663.6
GBSOL 25.863.4 33.563.6
GBELE 19.062.0 15.662.3
GBTOT 228.463.1 248.663.7
ELE, electrostatic interactions; VDW, van der Waals interactions between the
fragments; INT, internal energy arising from bond, angle and dihedral terms in
the MM force field; GAS, total gas phase energy (sum of ELE, VDW and INT);
PBSUR/GBSUR, nonpolar contribution to solvation; PBCAL/GB, the electrostatic
contribution to the solvation free energy calculated by PB or GB respectively;
PBSOL/GBSOL, sum of nonpolar and polar contributions to solvation; PBELE/
GBELE, sum of the electrostatic solvation free energy and MM electrostatic
energy; PBTOT/GBTOT, estimated total binding free energy calculated from the
terms above.
doi:10.1371/journal.pone.0035941.t001
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energy analysis. In total, more than 4000 snapshots were obtained,
and this amount was adequate for assessment of the whole binding
property of the two complexes.
It could easily be seen that the drug in the drug-sensitive R61
strainwas muchmore flexible than the drug inthedrug-resistant A7
strain (Figure 4B). This may indicate that the mutations had a large
effect on the interaction with the protein. However, after nearly
7 ns, the drug in the R61 strain began to converge with the RMSD
value, which fluctuated around 2.25 A ˚. This probably suggests that
the snapshots we extracted for computation were reasonable
because the whole complex and drug were equilibrated.
Binding Energies
We simulated the two complexes all for as long as 16 ns and
recorded the coordinate every 2 ps. As the equilibrium time was
Figure 1. Sequence alignment between PBP2x-R61 (R61), PBP2x-A7 (A7), and the template protein (PDB code 1QMF).
doi:10.1371/journal.pone.0035941.g001
Figure 2. Ramachandran plot of modeled PBP2x-R61 and PBP2x-A7. The most favored regions are red. Additionally allowed, generously
allowed, and disallowed regions are indicated as yellow, light yellow, and white, respectively.
doi:10.1371/journal.pone.0035941.g002
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computation, we chose the snapshot with an interval of 50, and
got a total of 80 representative snapshots. Due to the long intervals
between each snapshot, they were considered independent and
non-correlate. Thus, due to their ability to represent the whole
equilibrium process, they could be utilized to calculate the overall
binding energy.
MM-PBSA analysis was performed to evaluate the general
binding activity. Since these model structures were homology
modeling structures, the absolute values of these energies could
vary. The interaction energies corresponded only to the enthalpy
contributions of binding free energy. This could be found by
performing normal mode analysis. But, as we were studying two
proteins binding to the same ligand, a comparison of states of
similar entropy was desired; we did not take the entropy
contributions into consideration in practice. Another reason for
this was that normal mode analysis calculations were computa-
tionally expensive and tended toward a large margin of error. This
Figure 3. Comparison of PBP2x-R61 and PBP2x-A7. (A) The superimposition of initial structures of the complex between PBP2x-R61 (white
color) and PBP2x-A7 (cyan color) with the drug (green color). (B) The structure of the cefuroxime drug.
doi:10.1371/journal.pone.0035941.g003
Figure 4. RMSD values for PBP2x-R61-CES and PBP2x-A7-CES relative to the starting structure during MD simulation. (A) The whole
backbone atoms. (B) The drug molecule.
doi:10.1371/journal.pone.0035941.g004
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However, even with these qualifications, the relative importance
of each protein or residue could be inferred by its rank order of
interaction energy [52–53].
The binding energy results with standard deviations for every
energy item are shown in Table 1. Obviously, the fluctuation for
each item was reasonable. From the PBTOT or GBTOT item, it
could be easily seen that the difference between the overall binding
energy for the two complexes was very significant
(36.4217.2=19.2 kcal/mol). Even when taking the standard
deviation into consideration, the difference was still very distinct;
this confirmed that our comparison result was convincing. The
absolute energy contrast clearly indicated the huge binding affinity
difference; that is, the drug bound more tightly to PBP2x-A7 than
to PBP2x-R61. As a result, cefuroxime could prevent this protein
from executing its function in constructing the cell wall;
subsequently, it could kill the bacteria. But in S. suis R61, this
combining interaction was not strong enough to keep the protein
bound to the drug and keep the strain from functioning. The main
difference of the total energies could be attributed to the preferable
binding van der Waals and electrostatic terms (Table 1). The total
difference of these two parts reached 27.9 kcal/mol.
Energy Decomposition of Each Amino Acid Residue
The individual energy decompositions of all residues in the two
complexes were calculated in order to qualitatively find the key
residue that played a more important role in the cefuroxime
binding. Although the decomposition values were not so
quantitatively accurate, they did give a good indication for the
comparison of the corresponding residues. This was helpful for
location of the critical amino acids. Table 2 lists the residues for
which the absolute energy was larger than 1.0 kcal/mol or for
which the difference between the two complexes was larger than
0.5 kcal/mol. The absolute binding energy values of the conserved
Leu319, Trp376, Asn398, and Thr551 were very large in the two
complexes and this may reveal the universality of PBP protein
interaction with the drug. In contrast, the conserved Ser396,
Thr527, Ser549, and Gly550 had significantly different actions in
the two complexes and these residues preferred to bind more to
the drug for PBP2x-A7 than to the drug for PBP2x-R61. We
propose that this explicit difference owes to the general
conformation change of the two complexes. In fact, the RMSD
values of these two proteins increased to 7.26 A ˚, even before the
complete rotation of the drug molecule was considered (Data not
shown). By carefully investigating the mutated sites, the Asn569,
Leu594, and Val596 residues in PBP2x-A7 had much more
binding contribution than did the corresponding Gln569, Tyr594,
and Gly596 residues in PBP2x-R61. Besides these favoring PBP2x-
A7 residues, the Glu322 and Glu553 residues bound to the drug
more weakly than did the corresponding mutated PBP2x-R61
residues, Lys322, and Gln553. However, this kind of residue was
seldom, and the whole binding energy profile proved that PBP2x-
A7 generally bound much more tightly to cefuroxime (Figure 5). In
a word, these mutated residues played an important role in
changing the binding mode between S. suis R61 and the drug by
notable different binding energy contributions.
Furthermore, we paid attention to the residues 396–398 and
549–551 (Figure 5). These two regions were reported as the
conserved amino acid motifs acting as the active site of this enzyme
[13,54]. These two regions contributed much more in binding to
the drug in S. suis A7, while in S. suis R61 these residues had a
much lower binding ability (Table 2). In consequence, the final
drug resistance in S. suis R61 may due to the active site of PBP
protein, which is not so active in the R61 strain as in the sensitive
strain.
Hydrogen Bond Interaction
There were four hydrogen bonds in total between the protein
and the drug in the complex PBP2x-A7-CES, while there was only
one hydrogen bond in the complex PBP2x-R61-CES. Three
residues of Ser396, Gly550, and Thr551 formed those four
hydrogen bonds in PBP2x-A7-CES, and the last residue
contributed two hydrogen bonds. By plotting the distance of all
five hydrogen bonds in these two systems in the whole
equilibration process, it could be seen that bonds 1–4 were very
stable with cefuroxime in the complex PBP2x-R61 during the
whole simulation process (Figure 6A). But, the distance of
hydrogen bond Thr351 N-CES O5 was fluctuant and the angle
could not satisfy the criteria. Figure 6B shows the distance
variation results of these five hydrogen bonds in the PBP2x-A7-
CES complex. For bonds 1–4, the PBP2x-R61-CES distance was
much longer than the corresponding distances in the complex
PBP2x-A7-CES. This hydrogen bond distinction further verified
the more efficient binding to the drug for PBP2x-A7. With this
analysis, we could thus conclude that the hydrogen bond
differences of the active site residues greatly contributed to the
final drug resistance change for S. suis R61.
Although the Ser396, Gly550, and Thr551 residues were
conserved in the two proteins, they formed totally different
hydrogen binding networks in the two complexes. We speculate
this difference in hydrogen bond interaction may be attributed to
the structure conformation alteration. This change was also
verified by the energy contribution (Table 2, Figure 5). The
decomposed energies of these three residues in the PBP2x-A7-CES
complex were 22.20 kcal/mol (Ser396), 21.24 kcal/mol
(Gly550), and 22.93 kcal/mol (Thr551). The respective values
in the complex PBP2x-R61 with cefuroxime were 20.35 kcal/
mol, 20.56 kcal/mol, and 21.55 kcal/mol. These residues may
be a key factor in drug resistance change for S. suis R61 to
cefuroxime.
Hydrophobic Contact
The VDW item of the MM-PBSA and MM-GBSA in Table 1
mostly represents the nonpolar interaction: the hydrophobic
contact between the molecules. Though the two complexes,
PBP2x-A7-CES and PBP2x-R61-CES, all have large hydrophobic
effects, the former has an obviously much high contribution. This
can also be found by the decomposed energy contribution (Table 2
and Figure 5). Residues Leu319, Trp376, Phe451, Leu528,
Ala552, and Val571 in the two complexes all played a great role
in the hydrophobic contribution, while the residues in PBP2x-A7-
CES generally had a high value. Noticeably, mutant sites of
Tyr594 and Gly596 in PBP2x-R61-CES had a much lower value
compared to the corresponding hydrophobic amino acids Leu594
and Val596 in PBP2x-A7-CES. A similar trend is also shown in
the figure illustration in Figure 7. Overall, the hydrophobic
interaction was prevalent in the two studied complexes, but it was
more prominent for PBP2x-A7-CES. This probably indicates a
much higher binding affinity for PBP2x-A7 combining with the
drug than for PBP2x-R61. This result was in accordance with the
final resistance phenomenon.
Binding Mode Variation
The residues with the higher decomposed energy were found all
around the drug molecule; thus we investigated the residues apart
from the drug within 7 A ˚ in the two systems. By calculating the
distance, we found that for the complex PBP2x-R61-CES in the
MD Simulation of the Complex PBP2x with Cefuroxime
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were 34 residues in the PBP2x-A7-CES complex. After MD
simulation, the averaged structure for each system during the
whole equilibration phase was extracted to illustrate the binding
property. At this time, there were 27 residues apart from the drug
within 7 A ˚ in the PBP2x-R61-CES complex VS 37 residues in the
PBP2x-A7-CES complex. In the 27 residues of PBP2x-R61-CES,
23 residues formed 47 hydrogen bonds in the protein itself, while
36 residues in PBP2x-A7-CES formed 81 hydrogen bonds. This
demonstrated that the intermolecular interaction of the residues
around the drug was more popular in PBP2x-A7-CES than in
PBP2x-R61-CES. This probably changes the overall structure
conformation of this area and subsequently affects the interaction
between the PBP2x and the drug. These results indicated that
PBP2x-R61 had a looser interaction with the drug molecule, and
the binding mode exhibited combination differences with
cefuroxime as compared to PBP2x-A7 (Figure 7). Figure 7 gives
an explicit exhibition of the interaction profile between the
residues and the drug, according to the averaged structure. There
were more residues in PBP2x-A7 than in PBP2x-R61, and these
residues compactly surrounded the drug and interacted with it. In
addition, we listed the mutated residue pairs between PBP2x-R61
and PBP2x-A7 in this region (Table 3). Compared with the
residues in PBP2x-A7, the mutated residues 320, 321, 322, 553,
and 596 in PBP2x-R61 changed their property. The residues 373,
568, 569, and 595 remained the same. We speculate that these
residues were responsible for the different drug-resistance
phenomenon because they changed the topology conformation.
The Gln569 and Gly596 residues, however, contributed largely by
direct binding. The variation of the binding mode induced by
mutation was in agreement with the previous conclusions drawn
from hydrogen bond and energy analysis.
Conclusion
Hu et al.’s research indicated that S. suis R61 was resistant to the
drug b-lactam based on MIC test results. Further, the results
indicated that the resistance may be caused by the mutation of the
drug target PBP2x [23]. In order to study the drug-resistance
mechanism, 16 ns MD simulation for the two complexes of
PBP2x-A7 and PBP2x-R61 with cefuroxime were performed. By
applying the molecular modeling method, we obtained some
useful results about the detailed interaction between cefuroxime
and the protein. The MM-PBSA result firmly proved the tighter
binding to PBP2x-A7 as compared to the binding to PBP2x-R61.
This indicated the reason for S. suis R61 drug resistance against
cefuroxime. There were 4 stable hydrogen bonds supporting the
tight interaction between PBP2x-A7 and the drug, while there was
only one unstable hydrogen bond between PBP2x-R61 and the
drug. Besides, the residues forming hydrogen bonds all belonged to
Figure 5. Relative decomposed energies of the corresponding residues between PBP2x-R61-CES and PBP2x-A7-CES. The ovals
characterize the two active site areas and the blocks mark the three essential mutated residues.
doi:10.1371/journal.pone.0035941.g005
Table 2. The list of the residues with absolute energy larger
than 1.0 kcal/mol or the residues with the difference between
the two complexes larger than 0.5 kcal/mol.
Position PBP2x-A7-CES PBP2x-R61-CES
No. Residue
Energy
(kcal/mol) Residue
Energy
(kcal/mol)
319 Leu 21.84 Leu 21.27
322 Glu 0.17 Lys 20.34
376 Trp 23.57 Trp 24.80
396 Ser 22.20 Ser 20.35
398 Asn 21.65 Asn 21.40
527 Thr 21.30 Thr 20.54
548 Lys 20.96 Lys 0.06
549 Ser 22.73 Ser 0.09
550 Gly 21.24 Gly 20.56
551 Thr 22.93 Thr 21.55
567 Tyr 20.82 Tyr 20.09
569 Asn 21.23 Gln 0.02
571 Val 20.63 Val 20.01
594 Leu 22.01 Tyr 20.01
596 Val 20.58 Gly 0.01
doi:10.1371/journal.pone.0035941.t002
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35941Figure 6. The distance variation of the five hydrogen bonds during MD simulation. (A) for PBP2x-R61-CES. (B) for PBP2x-A7-CES. Bond 1:
Ser396 O - CES O7; Bond 2: Gly350 N - CES O3; Bond 3: Thr351 OG1 - CES N2; Bond 4:Thr351 OG1 - CES O5; and Bond 5: Thr351 N - CES O5.
doi:10.1371/journal.pone.0035941.g006
Figure 7. LIGPLOT representation of cefuroxime (CES) binding to PBP2x-R61 and PBP2x-A7. Ligand, protein, and hydrogen bonds are in
thick blue, thick brown, and broken green lines, respectively. Residues involved in hydrophobic contact are associated with a curved comb. (A) Open
form of cefuroxime (CES) bound to PBP2x-R61. (B) Open form of cefuroxime (CES) bound to PBP2x-A7.
doi:10.1371/journal.pone.0035941.g007
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PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e35941the conserved active site area. This region has been reported to
play an essential role in the interaction with the drug, and this can
be further verified by energy decomposition analysis. As a result,
the much lower contribution of the active site area in PBP2x-R61
was one important reason for S. suis’s drug resistance. Moreover,
mutated sites 569, 594, and 596 were recognized as the key
mutations. In PBP2x-A7 these residues contributed much more to
drug binding to the drug, whereas they showed little contribution
in PBP2x-R61. Because the structure conformation of the residues
surrounding the drug in the binding site had a big difference, it
could be concluded that the mutated residues induced the loose
interaction between PBP2x-R61 and the drug. To our knowledge,
our study has been the first investigation using the MD method to
compare the specific interaction between PBP2x proteins and the
drug in drug-sensitive and drug-resistant Streptococcus suis. These
results will be helpful for further work on antibiotics and drug
design.
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